Haemonetics Corporation has completed its acquisition of OpSens, the company announced in a press release today.
Haemonetics acquired all outstanding shares of OpSens for CAD$2.90 per share in the all-cash transaction, representing a fully diluted equity value of approximately US$255 million at the current exchange rate.
“Expanding our hospital portfolio with OpSens’ products creates exciting growth and diversification opportunities, while providing immediately accretive financial benefits,” said Chris Simon, Haemonetics’ president and chief executive officer. “We are pleased to officially welcome OpSens to Haemonetics and look forward to driving greater access to OpSens’ essential solutions and benefits for physicians and patients throughout the world.”
OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology. Core products include SavvyWire, a sensor-guided three-in-one guidewire for transcatheter aortic valve implantation (TAVI) procedures, that acts as a pacing and pressure monitoring wire, as well as OptoWire, a pressure guidewire that aims to improve clinical outcomes by measuring fractional flow reserve (FFR) and diastolic pressure ratio (dPR) to aid clinicians in the diagnosis and treatment of patients with coronary artery disease.
OpSens also manufactures a range of fibre optic sensor solutions used in medical devices and other critical industrial applications.
